Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- More generics receive clearance for marketing by the FDA
- WASHINGTON -- The Actavis Group has received Food and Drug Administration approval to market bupropion hydrochloride extended-release tablets, 150 mg. The company also markets a 300-mg version of the product, indicated for the treatment of major depressive disorder. Annual sales of brand and generic versions of the drug in...
- Research articles 2008-12-08
- 'Father of LSD' takes final trip
- GENEVA AFP — Albert Hofmann, the Swiss chemist who discovered the now-banned hallucinogenic drug LSD that was an icon of the Hippy movement, has died at the age of 102, authorities said Wednesday. The scientist, born in Baden in northern Switzerland in 1906, worked for chemicals company Sandoz from...
- Research articles 2008-04-30
- Generics Giant Sandoz Completes $10 Million Expansion in North Carolina, an Industrial Info News Alert
- Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- Dovetailing nicely with the continuing demand for generic drug products, Sandoz has completed a $10 million expansion at its Wilson, North Carolina, Center of Excellence site. The project added 30,000 square feet to the 170,000-square-foot facility. Sandoz is the...
- Research articles 2007-12-28
- Sanofi fighting generic drugs tooth and nail in US courts
- PARIS AFP — The French pharmaceuticals group Sanofi-Aventis is turning to vigorous legal action to protect its best-selling drugs in the United States from cheaper generic competition. "We are sure of our patents," a spokesman for Sanofi-Aventis, the world's third largest drug group, said Wednesday. Sanofi announced it...
- Research articles 2006-08-09
- Research & Markets: With Sales of Over US$4.6 Billion Sandoz is Currently the Second Largest Generic Manufacturer in the World
- DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c36147) has announced the addition of the Espicom Business Intelligence Ltd report: Sandoz Generics Company Intelligence Report to their offering.
- Research articles 2007-05-30
- Think what's possible.(pharmaceutical industry)
- Novartis AG (NYSE: NVS) is a world leader in pharmaceuticals and consumer health. In 2003, the Group's businesses achieved sales of $24.9 billion and a net income of $5.0 billion. The Group invested approximately $3.8 billion in Research & Development. Headquartered in Based, Switzerland, Novartis Group...
- Research articles 2005-03-01
- Frost & Sullivan Award Recognises Sandoz's Competitive Strategy Leadership in Global Biopharmaceutical Market.
- LONDON, February 16 /PRNewswire/ -- The 2004 Frost & Sullivan Competitive Strategy Leadership Award is presented to Sandoz for its clear demonstration of gains in market share through development of innovative and high-quality solutions for the overall growth of the biopharmaceuticals industry....
- Research articles 2005-02-16
- Azelis
- Pan-European chemicals distributor Azelis has appointed Hanspeter Knoepfel as its first chairman. Knoepfel's task will be to support Azelis chief executive Hans Udo Wenzel by focusing on corporate governance and non-commercial organisational matters. He has had a long career in chemicals, including posts with Sandoz and Clariant.
- Research articles 2004-11-01
- Research and Markets: Gain an Understanding of the Complex Issues Affecting Sandoz the Generics Company
- DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c36147) has announced the addition of the Espicom Business Intelligence Ltd report: Sandoz Generics Company Intelligence Report to their offering.
- Research articles 2006-04-26
- Biotech
- Novartis subsidiary Sandoz estimates that by 2007, biotech drugs with more than $16 million in sales will go off patent. In fact, the European patent for synthetic human hormone EPO expires this December. However, most biotech companies estimate that biogenerics are four to seven years away from market. Besides the...
- Research articles 2004-06-15
- AstraZeneca sells Durascan Medical A/S to Sandoz
- NORDIC BUSINESS REPORT-30 June 2004-AstraZeneca sells Durascan Medical A/S to SandozC1994-2004 M2 COMMUNICATIONS LTD http://www.m2.com
- Research articles 2004-06-30
- 340B Prime Vendor Program Adds Sandoz Pharmaceuticals to Growing List of Companies Providing Low-Income Americans With Access to Antibiotic Injectibles and Oral Solid Medications
- The 340B Prime Vendor Program, managed by HealthCare Purchasing Partners International® HPPI announced today that it has added global pharmaceutical leader Sandoz a division of Novartis to its growing list of companies providing drugs, supplies and medical devices to clinics, hospitals and health care programs for low-income Americans. HPPI's three-year...
- Research articles 2006-04-10
- Wilson.(EASTERN)
- WILSON -- Sandoz, part of Swiss drug maker Novartis, plans to spend $10 million to expand research and development and add 65 jobs here within ... WILSON -- Sandoz, part of Swiss drug maker Novartis, plans to spend $10 million to expand research and development and...
- Research articles 2006-07-01
- Sandoz Sets Up New Plant In India
- Sandoz, the generics division of drug maker Novartis, has invested US$13 million in a third production facility in India. The investment is part of the company's global expansion of production facilities.
- Research articles 2004-05-23
- Novartis revives Sandoz brand name. (News: Europe).(Brief Article)
- NOVARTIS AG is reviving the name Sandoz as an umbrella brand for its global operations in generic medicines. Since the merger of Sandoz and Ciba-Geigy to form Novartis seven years ago, the 117 year-old Sandoz name has been used on only a...
- Research articles 2003-01-27
- LETTERS
- Lengthy Disputes Cheers to James Gardner for his review [June 30] of Mason & Dixon by Thomas Pynchon--surely one of this century's most overrated writers. As an undergraduate, I had an English professor who included Gravity's Rainbow on the syllabus. After fifty bizarre and largely incomprehensible pages, I gave...
- Research articles 1997-07-28
- Changing of the Guard
- Restructuring is underway in the multi-billion dollar global specialty chemicals industry, with several high profile moves in 1996 and 1997. These changes are occurring right at the top with two new players--Clariant and Ciba Specialty Chemicals CSC--moving into the No. 1 and No. 2 spots, respectively....
- Research articles 1997-04-28
- Away win for the Morgans. (Morgan Stanley and JP Morgan's consultancy services in the Sandoz and Ciba merger)
- US investment banks JP Morgan and Morgan Stanley have acquired the right to provide financial advisory services to the merger of Swiss drug firms Sandoz and Ciba to form Novartis. As a result, questions were raised on why the firms have not acquired the services of Swiss banks. However, the...
- Research articles 1996-04-01
- European pesticides: companies face up to a declining market.
- Declining domestic demand has made consolidation imperative for European pesticides makers. Changes in the European Common Agricultural Policy and adverse weather combined to reduce sales by 13.5% in 1992. High R&D costs, fueled by the transition from chemically to biologically based products, is also forcing companies to consolidate. Schering, BASF,...
- Research articles 1993-06-02
- INDIA: SANDOZ SETS UP NEW PLANT IN INDIA.
- Sandoz, the generics division of drug maker Novartis, has invested US$13 million in a third production facility in India. The investment is part of the company's global expansion of production facilities. The new unit will ... Sandoz, the generics division of drug maker Novartis, has...
- Research articles 2004-05-23
- << Previous
- page 1 of 2
- Next >>
Content Types
Refining Tags
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
